MeSH D003929 - diabetic neuropathies
Favorite
Competitive Landscape
Events Timeline
Commercial
Clinical Trials
Competitive landscape
Events Timeline
Commercial
Company Name | Drug Name | Trade Name | Patent Expires | Approval Date | Revenue | Period |
|---|---|---|---|---|---|---|
| Teva | Duloxetine | Duloxetine | 2013-12-11 | |||
| Mexiletine | Mexiletine | 1995-05-16 | ||||
| Novast Laboratories | Mexiletine | Mexiletine | 2021-01-25 | |||
| Mylan | Duloxetine | Duloxetine Mylan | 2015-06-19 | |||
| Johnson & Johnson | Becaplermin | Regranex | 1999-03-29 | |||
| Lupin Research | Duloxetine | Duloxetine | 2013-12-11 | |||
| Boehringer Ingelheim | Duloxetine | Duloxetine Boehringer Ingelheim | 2008-10-08 | |||
| Mexiletine | Mexitil | 1985-12-30 |
1
2
3
4
5
6
7
>
Clinical Trials
Historical Success Rate
Phase 1
58%7/12
Phase 2
58%29/50
Phase 3
44%23/52
Approved: 8Overall Success rate: 15%
All Clinical Trials
Therapeutic Areas:
All
Classification:
All
Approval:
All
Status:
All
Phases:
All
Company name | Phase 1 | Phase 2 | Phase 3 | Phase 4 | Drug Name |
|---|---|---|---|---|---|
1
2
3
4
5
>
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use